Should you be able to pick your baby's genetic code?

Key Concepts

• In Vitro Fertilization (IVF): A process of fertilization where an egg is combined with sperm outside the body, in vitro.
• Genetic Screening/Pre-implantation Genetic Diagnosis (PGD): Testing of embryos created through IVF for genetic defects or predispositions before implantation.
• Nucleus Genomics: A US-based startup offering genetic optimization services for IVF embryos.
• Polygenic Risk Score (PRS): A score that estimates an individual's genetic predisposition to a particular trait or condition based on the combined effect of many genes.
• Eugenics: The practice or advocacy of improving the human species by selective breeding, often through the elimination of "undesirable" genes.
• Pronatalism: The advocacy of policies that encourage childbearing.

Genetic Optimization of Embryos: The New Frontier in Fertility Science

This report delves into the emerging practice of genetically optimizing IVF embryos, a service offered by US startup Nucleus Genomics, and explores its implications, ethical considerations, and potential future trajectory.

1. The Service Offered by Nucleus Genomics

Nucleus Genomics, a New York-based startup, is offering parents undergoing IVF the ability to perform a full DNA profile on their fertilized but not yet implanted embryos. This service extends to up to 20 embryos, allowing parents to "genetically optimize" their chosen embryo.

• Core Offering: Full DNA sequencing of IVF embryos.
• Purpose: To "genetically optimize" embryos, which includes reducing the risk of disease and potentially selecting for traits like height and intelligence.
• Target Audience: Parents undergoing IVF.
• Marketing: Advertisements have appeared on the New York subway system, promoting the idea of choosing a "best baby" with "great genes."

2. Scope of Genetic Testing and Selection

The service offered by Nucleus Genomics goes beyond the established practices in some regions.

• Standard Practice (UK/Europe): Genetic screening is permitted for inherited fatal or life-limiting diseases. Gender selection is also allowed if the disease is gender-linked.
• Nucleus Genomics' Extended Offering:
  • Disease Avoidance: Beyond rare fatal conditions, they offer screening for more common conditions like heart disease, schizophrenia, autism, and ADHD.
  • Trait Selection: They also claim to provide genetic information and selection for traits such as height, intelligence, and eye color.

3. Technical Aspects and Limitations of Polygenic Risk Scores

The selection for complex traits like height and intelligence relies on Polygenic Risk Scores (PRS), which have significant limitations.

• Nature of Complex Traits: Traits like height and eye color are not determined by a single gene but by the interplay of numerous genes and environmental factors (e.g., nutrition, lifestyle).
• Polygenic Risk Score (PRS): This is a statistical estimate based on sequencing large populations of genomes (e.g., UK Biobank with 500,000 genomes). It indicates where an embryo's genetic sequence might lie on a spectrum for a particular trait.
• Lack of Guarantee: PRS provides a "statistical guess" and is "by no means guaranteed." For example, a 70% score for being taller than average does not ensure the child will be taller than average.
• Data Bias: Current PRS are often based on genomes from specific demographics (e.g., white, middle-class Europeans), limiting their accuracy for individuals from different ethnic backgrounds.
• Community View: The broader human genetics community, including the American Society for Reproductive Medicine, advises against using PRS for embryo selection due to its unreliability.

4. Ethical and Societal Implications

The ability to genetically select embryos raises profound ethical questions and concerns.

• The "Should You?" Question: While parents may desire to ensure their child has a long and happy life, the ethical implications of selection are debated.
• Unintended Consequences: Tinkering with genes for specific traits could inadvertently screen out other beneficial genes or disrupt the complex genetic makeup that has evolved over millions of years. For instance, selecting against genes associated with autism might also impact genes related to intelligence.
• The "Designer Baby" Concept: The prospect of selecting for non-medical traits like intelligence and height evokes concerns about creating a genetically enhanced elite.
• Eugenics Concerns: The practice is seen by some as resembling eugenics, raising fears of a return to discriminatory selective breeding.
• Societal Divide: There's a concern that such technologies could create a divide between a wealthy elite who can afford genetic optimization and the rest of the population.

5. The Silicon Valley Connection

There are notable links between the founders of companies like Nucleus Genomics and prominent figures in Silicon Valley.

• Pronatalism and Longevity: Figures like Elon Musk and Peter Thiel are interested in increasing human population and longevity, and investing in genetic research.
• Funding and Mentorship: Keon Sardigi, the 25-year-old founder of Nucleus Genomics, was a graduate of Peter Thiel's founders program and received funding from him.
• Vision of "Coding for Life": This connection highlights a broader Silicon Valley ethos of using technology and data to "code for healthier, longer-lived children."

6. Legal Landscape and Future Outlook

The legal framework surrounding these technologies varies significantly by region.

• United Kingdom: IVF and PGD are strictly regulated. Genetic testing is licensed and permitted only for medically relevant, fatal, or life-limiting inherited disorders.
• United States: There are no federal or state rules governing what IVF clinics can test for in embryos, allowing for a broader range of services.
• Global Variation: Similar strict regulations exist in most European countries, while the US and a few other nations have fewer restrictions.
• Evolving Technology: While current PRS are unreliable, the technology and databases are constantly improving, suggesting that the capabilities and ethical debates will continue to evolve.

7. Conclusion and Key Takeaways

The intersection of IVF and genetic screening presents a complex and rapidly developing field. While the ability to screen for and prevent serious inherited diseases offers significant benefits and has become ethically accepted, the extension to selecting for non-medical traits like height and intelligence raises profound ethical, societal, and technical challenges. The current unreliability of polygenic risk scores for these traits, coupled with the potential for unintended consequences and the influence of Silicon Valley's pronatalist and longevity-focused agenda, suggests that society is at a critical juncture in navigating the future of reproductive genetics. The legal and ethical frameworks will need to adapt to these advancements, with the UK's stringent regulations serving as a contrast to the more permissive environment in the US. The discussion around "designer babies" is far from over and will likely intensify as the technology progresses.